BRIEF published on 04/01/2026 at 07:35, 4 months 9 days ago MaaT Pharma Presents CHRONOS Study Results on Third-Line Acute GvHD MaaT Pharma Regulatory Review CHRONOS Study Acute GvHD Third-line Therapy
BRIEF published on 04/01/2026 at 07:35, 4 months 9 days ago MaaT Pharma publie des données sur l'aGvH dans "Bone Marrow Transplantation" MaaT Pharma EMA AGvH Xervyteg® CHRONOS
BRIEF published on 04/01/2026 at 07:35, 4 months 9 days ago MaaT Pharma publishes data on aGvH in "Bone Marrow Transplantation" MaaT Pharma EMA AGvH Xervyteg® CHRONOS
PRESS RELEASE published on 04/01/2026 at 07:30, 4 months 9 days ago Inside Information / Other news releases MaaT Pharma announces publication of retrospective data from CHRONOS study in Bone Marrow Transplantation Journal, presenting real-world outcomes of third-line systemic treatments for GI-aGvHD patients MaaT Pharma GI-aGvHD CHRONOS Study Retrospective Data Bone Marrow Transplantation
PRESS RELEASE published on 04/01/2026 at 07:30, 4 months 9 days ago Informations privilégiées / Autres communiqués MaaT Pharma publie des données rétrospectives de l'étude CHRONOS sur la maladie aiguë du greffon contre l'hôte (aGvH) dans Bone Marrow Transplantation. Résultats présentés au congrès annuel 2026 de l'EBMT MaaT Pharma Étude Bone Marrow Transplantation CHRONOS Maladie Aiguë Du Greffon Contre L'hôte
BRIEF published on 03/31/2026 at 07:35, 4 months 10 days ago MaaT Pharma : Chiffre d'Affaires 2025 et Progrès Cliniques Chiffre D'affaires Financement Développement Clinique MaaT Pharma Microbiothérapies
BRIEF published on 03/31/2026 at 07:35, 4 months 10 days ago MaaT Pharma: 2025 Revenue and Clinical Progress Revenue Funding Clinical Development MaaT Pharma Microbiothérapies
PRESS RELEASE published on 03/31/2026 at 07:30, 4 months 10 days ago Informations privilégiées / Information sur chiffre d’affaires annuel MaaT Pharma annonce ses résultats annuels pour l'année 2025 et fait le point sur ses activités. Avancées MaaT013, pipeline MaaT033 et MaaT034, accord de financement, trésorerie et perspectives de développement Développement Résultats Annuels Pipeline MaaT Pharma Accord Financement
BRIEF published on 01/20/2026 at 18:35, 6 months 21 days ago MaaT Pharma Launches Phase 2 Trial for NSCLC Patients NSCLC MaaT Pharma Gut Microbiome IMMUNOLIFE Phase 2 Antibiotic-induced Dysbiosis
BRIEF published on 01/20/2026 at 18:35, 6 months 21 days ago MaaT Pharma lance un essai de phase 2 pour les patients atteints de CBNPC MaaT Pharma IMMUNOLIFE Phase 2 CBNPC Microbiote Intestinal Dysbiose Induite Par Les Antibiotiques
Published on 08/11/2026 at 00:40, 1 hour 21 minutes ago CORRECTION FROM SOURCE: Fermi Announces Binding Lease Agreement with TensorWave
Published on 08/11/2026 at 00:25, 1 hour 36 minutes ago Empress Reports 2026 Second Quarter Financial Results
Published on 08/10/2026 at 23:35, 2 hours 26 minutes ago NioCorp Project to Expand Production to 8 Made-in-USA Critical Minerals Over a 40-Year Mine Life with an Estimated $4.1 Billion Pre-Tax NPV8%
Published on 08/10/2026 at 23:30, 2 hours 31 minutes ago Condor and Element79 Agree on Restructured Terms for Lucero Project
Published on 08/10/2026 at 23:25, 2 hours 36 minutes ago Ur-Energy Reports Second Quarter 2026 Results
Published on 08/10/2026 at 22:15, 3 hours 46 minutes ago Amrize Files Form 10-Q for Second Quarter 2026
Published on 08/10/2026 at 22:05, 3 hours 56 minutes ago Immunic Appoints Elena Ridloff to Board of Directors
Published on 08/10/2026 at 20:24, 5 hours 37 minutes ago EQS-Adhoc: PNE AG updates on ongoing sales process
Published on 08/10/2026 at 19:35, 6 hours 26 minutes ago Kontron AG: All conditions of the mandatory tender offer of Ennoconn Corporation are met – Settlement will take place shortly
Published on 08/10/2026 at 19:00, 7 hours 1 minute ago PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 03 AOUT 2026 au 07 AOUT 2026
Published on 08/10/2026 at 18:00, 8 hours 1 minute ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 8 hours 1 minute ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 8 hours 16 minutes ago Déclaration hebdomadaire de rachat d'actions
Published on 08/10/2026 at 11:53, 14 hours 7 minutes ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
